Agilent Technologies, Inc.
Analysis
Three quarters into FY2026, Agilent has raised its full-year outlook at every call, and the raises come from its own pricing and cost programme rather than a stronger market. The question has shifted from recovery to execution. How much of Agilent's FY2027 growth is already booked?
- Agilent has raised its full-year outlook at every call this year.
Management began FY2026 guiding 4% to 6% growth and has raised that outlook every quarter since, mostly on its own pricing and cost programme, Ignite. It now adds roughly 2% of price a quarter, so more of each sale reaches profit.
- The instrument replacement cycle has turned into a booked annuity.
Instrument orders have topped revenue for ten straight quarters, and the new GC launches sold at double the planned rate. Each instrument pulls years of consumables and service behind it, so the base keeps earning after the sale. How much of Agilent's revenue is recurring service and consumables?
- Agilent's fastest-growing business is about to lap itself.
Its CDMO arm behind the GLP-1 boom grew nearly 30% in Q3 FY2026, but Q4 is guided flat against a 40% comparison and the next plant opens in spring 2027 — costs land a year before the sales. The weakest quarters set up the next step. When does Agilent's new Train C plant start paying for itself?
- Ignite operating systemIgnite has turned pricing, procurement and manufacturing discipline into a repeatable source of margin rather than a one-time cost program.
- Instrument replacement cycleInstrument demand rests on aging customer fleets, so replacement purchases and share gains can keep growth ahead of the market.
- Pharma and chip reshoringPharma and semiconductor reshoring adds laboratory capacity that is built around the company's chromatography and spectroscopy tools.
- Academic and China spendingGrowth leans on academic and government budgets that keep falling and on China, where orders swing with stimulus timing.
- One-time tariff refundsThe latest margin gain leaned on tariff refunds and on pricing that may be harder to repeat as input costs rise.
- CDMO batch timing and customersThe specialty CDMO business depends on a few large customers and lumpy batch schedules while new capacity ramps.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Purchase | ≥$1K | May 18 | Jul 1 |
Donald Trump Republican · Executive | Sale | ≥$1K | Mar 27 | May 13 |
Donald Trump Republican · Executive | Purchase | ≥$15K | Mar 23 | May 13 |
Donald Trump Republican · Executive | Sale | ≥$50K | Mar 18 | May 13 |
Donald Trump Republican · Executive | Sale | ≥$1K | Mar 17 | May 13 |
Congressional trading data provided by QuiverQuant
How Agilent Technologies turned $6.9B of revenue into $1.5B of operating income.
| Revenue | ||
|---|---|---|
| Agilent CrossLab | $2.9B | ▲ 76.89% YoY |
| Life Sciences and Applied Markets | $2.7B | ▼ 15.21% YoY |
| Applied Markets | $1.3B | |
| Total revenue | $6.9B | |
| Gross profit | $3.6B | 52.4% |
| Operating income | $1.5B | 21.3% |